- Home
- SEGG vs HOTH Comparison
SEGG vs HOTH Comparison
Compare SEGG & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | HOTH |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 17.7M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SEGG | HOTH |
|---|---|---|
| Price | $1.26 | $0.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $5.00 |
| AVG Volume (30 Days) | ★ 3.7M | 3.3M |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.49 |
| 52 Week High | $7.61 | $2.12 |
Technical Indicators
Market Signals| Indicator | SEGG | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 45.03 |
| Support Level | $1.06 | $0.49 |
| Resistance Level | $1.56 | $0.78 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 66.38 | 68.51 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a sports, entertainment and gaming group operating digital assets such as Sports.com and Lottery.com. It is focused on immersive fan engagement, ethical gaming and AI-driven live experiences.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).